Skip to main content

Table 1 Baseline characteristics of patients with and without acute pulmonary embolism

From: Predictors and outcomes of acute pulmonary embolism in COVID-19; insights from US National COVID cohort collaborative

 

Pulmonary embolism COVID-19 patients

(n = 1117)

Non-pulmonary embolism COVID-19 patients

(n = 30,383)

Odds ratio, p value

Age ± SD

62 ±  (15.1)

57 ±  (19.7)

1.014 (1.011–1.018), p < 0.001

Females

474 (42%)

15,180 (49%)

0.73 (0.65–0.83), p < 0.001

Race

   

 Caucasians

555 (49%)

15,513 (51%)

0.94 (0.84–1.06), p = 0.36

 African American

378 (33%)

8361 (27.5%)

1.34 (1.18–1.52), p < 0.001

 Asian American

38 (3.4%)

719 (2.3%)

1.45 (1.04–2.2), p = 0.02

 Others

168 (15%)

5790 (19%)

0.75 (0.63–0.88), p < 0.001

Atrial fibrillation/flutter

168 (15%)

3685 (12.1%)

1.28 (1.08–1.51), p = 0.003

HTN

677 (60.6%)

15,817 (52%)

1.41 (1.25–1.60), p < 0.001

Diabetes

393 (35.1%)

8317 (27.3%)

1.44 (1.27–1.63), p < 0.001

Atherosclerosis

171 (15.3%)

4350 (14.3%)

1.08 (0.91–1.27), p = 0.35

Acute kidney injury

472 (42.2%)

8459 (27.8%)

1.89 (1.67–2.14), p < 0.001

Chronic kidney disease

156 (13.9%)

3588 (11.8%)

1.21 (1.02–1.44), p = 0.02

Congestive heart failure

234 (20.9%)

5085 (16.7%)

1.31 (1.13–1.52), p < 0.001

Chronic obstructive pulmonary disease

116 (10.3%)

3098 (10.19%)

1.02 (0.83–1.24), p = 0.83

Obstructive sleep apnea

178 (15.9%)

3922 (12.9%)

1.27 (1.08–1.50), p = 0.003

Sepsis

386 (34.5%)

6742 (22.1%)

1.85 (1.63–2.1), p < 0.001

Hypothyroidism

148 (13.2%)

3601 (11.8%)

1.13 (0.95–141), p = 0.15

Obesity

339 (30.3%)

7251 (23.8%)

1.39 (1.22–1.58), p < 0.001

Malignancy

68 (6%)

766 (2.5%)

2.5 (1.94–3.23), p < 0.001

Anemia

366 (32.7%)

7106 (23.3%)

1.59 (1.40–1.81), p < 0.001

Nicotine dependence

107 (9.5%)

3118 (10.2%)

0.92 (0.75–1.13), p = 0.45

Acute DVT of extremities

102 (9%)

66 (0.2%)

46.16 (33.65–63.3), p < 0.001

Acute encephalopathy

125 (11.2%)

1819 (6%)

1.98 (1.63–2.39), p < 0.001

Stroke/cerebrovascular diseases

65 (5.8%)

1077 (3.5%)

1.66 (1.28–2.18), p < 0.001

Steroids

610 (54%)

11,653 (38.3%)

1.93 (1.71–2.18), p < 0.001

Remdesivir

311 (27%)

5746 (18.9%)

1.65 (1.45–1.89), p < 0.001

Tocilizumab

32 (2%)

410 (1.3%)

2.15 (1.49–3.10), p < 0.001

Hydroxychloroquine

86 (7.6%)

2020 (6.6%)

1.17 (0.93–1.46), p = 0.17